DRIO übertreffen die 19 der letzten 36Schätzungen.
53%
Nächster Bericht
Datum des nächsten Berichts
09. März 2026
Estimate forQ4 25(Revenue/ EPS)
$5.27M
/
-$3.66
Implizierte Änderung vonQ3 25(Revenue/ EPS)
+5.18%
/
-223.65%
Implizierte Änderung vonQ4 24(Revenue/ EPS)
-30.74%
/
+103.33%
DarioHealth Corp. Common Stock earnings per share and revenue
On 13. Nov. 2025, DRIO reported earnings of 2.96 USD per share (EPS) for Q3 25, beating the estimate of -4.99 USD, resulting in a 159.22% surprise. Revenue reached 5.01 million, compared to an expected 5.78 million, with a -13.35% difference. The market reacted with a -15.57% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analysts forecast an EPS of -3.66 USD, with revenue projected to reach 5.27 million USD, implying an decrease of -223.65% EPS, and increase of 5.18% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AngioDynamics, Inc.
Report Date
06. Jan. 2026 For Q2 26
Estimate
-$0.10
Aktuell
$0.00
Überraschung
+100.00%
FAQ
What were DarioHealth Corp. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, DarioHealth Corp. Common Stock reported EPS of $2.96, beating estimates by 159.22%, and revenue of $5.01M, -13.35% below expectations.
How did the market react to DarioHealth Corp. Common Stock's Q3 2025 earnings?
The stock price moved down -15.57%, changed from $11.75 before the earnings release to $9.92 the day after.
When is DarioHealth Corp. Common Stock expected to report next?
The next earning report is scheduled for 09. März 2026.
What are the forecasts for DarioHealth Corp. Common Stock's next earnings report?
Based on 6
analysts, DarioHealth Corp. Common Stock is expected to report EPS of -$3.66 and revenue of $5.27M for Q4 2025.